Treatment of Diabetic Foot Ulcers With AUP1602-C

NCT ID: NCT04281992

Last Updated: 2023-09-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 26 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-01-28
• Study Completion Date: 2023-03-20

Brief Summary

This is a two-part phase 1/2A study performed in diabetic foot ulcer (DFU) patients with chronic non-healing wounds to investigate the safety and efficacy of AUP1602-C.

Detailed Description

Study AP-W-CLI-2018-8 is the first clinical study of AUP1602-C in humans. It is a Phase 1/2A clinical study to evaluate the safety, tolerability and efficacy of a single and repeated doses of AUP-16 as topical treatment of DFU. The Phase 1 part will be a multicenter, open-label, non-randomized, uncontrolled dose-finding study with sequential dose escalations performed in dose cohorts comparing three doses of AUP-16 administered three times per week (low, medium, and high dose cohorts). This part will consist of four sequentially recruited cohorts. It is expected that a minimum of 15 patients may be required to determine the RP2D in phase 1 part.

The Phase 2A part, an extension of the Phase 1, will be a multi-center, open-label, randomized, placebo-controlled study of the recommended AUP1602-C dose and administration schedule from Phase 1 to confirm safety and to assess efficacy of the selected recommended phase 2 dose and schedule in DFU patients.

Conditions

Diabetic Foot Ulcer

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

AUP1602-C

AUP1602-C will be administered topically once or repeatedly three times per week during the treatment period.

Group Type: EXPERIMENTAL

AUP1602-C

Intervention Type: BIOLOGICAL

AUP1602-C is topically applied on chronic wounds and covered by wound dressing.

Interventions

AUP1602-C

AUP1602-C is topically applied on chronic wounds and covered by wound dressing.

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Male or female patients aged 18 to 80 years

2. Patients with DM of type 1 or 2 having a glycosylated haemoglobin (HbA1c) of ≤11% and a serum creatinine level of ≤1.5 times the upper limit of normal (ULN)

3. Patients with at least one ulcer that fulfills all of the following criteria at screening and at baseline (prior to treatment start)

• Present for ≥1 month
• Located either in the plantar or on the dorsum of foot, or in the distal part of the leg, around the malleolar areato be accessible for administration of AUP1602-C/placebo and to be completely covered by the primary and secondary dressings
• Partial- or full-thickness, not involving bone or joints, i.e. University of Texas classification Grade 1A, 1C, 2A or 2C.
• No clinical signs of active infection or osteomyelitis
• Size of the target ulcer for DFU must be between 1-9 cm2 after debridement
• Chronic target ulcer, defined as <30% reduction in size in response to SoC during the 2-week screening period
• Target ulcer appropriately debrided (<10% black and at least 50% of red/pink on a colorimetric scale)
• Ulcer and periwound tissue suitable to using film dressings (i.e. no contraindications [e.g.: excessive exudation, maceration] and sufficient periwound space to hold the dressing)

4. Patients with more than one ulcer will be included if ulcers are separated by a minimum of 5 cm healthy tissue but only one target ulcer will be selected for the investigational treatment (based on investigator decision)

5. Patients with an ankle brachial index (ABI) ≥0.7 on the foot with the target ulcer

6. Patients with an assessment of the baseline level of neuropathy of the foot using Semmes-Weinstein monofilaments

7. Patients must adhere to wear therapeutic shoes or off-loading footwear if indicated

8. A female patient of childbearing potential must have a negative serum pregnancy test at the time of Screening

9. Patients must use a highly effective contraceptive measure (methods that can achieve a failure rate of less than 1% per year when used consistently and correctly), like hormonal contraception (oral pills, implantable device, or skin patch), intrauterine device, bilateral tubal occlusion, or double barrier throughout the study

10. Patients who understand and are willing to comply with study procedures and give written informed consent prior to enrolment in the study or initiation of study procedures

Exclusion Criteria

1. Current or previous (within 2 weeks prior to start of screening/run-in period) treatment with another investigational drug and/or medical device or participation in another clinical study

2. Current or previous (within 30 days prior to start of screening/run-in period) treatment with a biologic agent, growth factors or skin equivalents (e.g. Regranex®, Apligraf®, or Dermagraft®)

3. Current or previous (within 2 weeks prior to first study drug dosing) treatment with active wound care agents (e.g. local and systemic antibiotics or silver dressings)

4. Current or previous (within 2 weeks prior to first study drug dosing) use of corticosteroids and immunosuppressants

5. Known hypersensitivity to any of the investigational drug or vehicle components

6. Ulcer of University of Texas Grade ≥2, with deep abscess, or gangrene

7. Target ulcer with known or suspected active infection which requires antimicrobials. Any antibiotic therapy must be completed or discontinued within 2 weeks prior to first study drug dosing

8. Target ulcer positive for MRSA

9. Target ulcer other than chronic non-healing DFU (e.g. pressure ulcers, burn wounds)

10. Prior radiation therapy (within 6 weeks prior to first study drug dosing) of any part of the foot/leg bearing the target ulcer under study

11. Sickle-cell anemia, Reynaud's, or other peripheral vascular disease including venous leg ulcers

12. Infective endocarditis or increased risk for infective endocarditis, which includes, but is not limited to, prosthetic cardiac valve or prosthetic material used for cardiac valve repair, previous infective endocarditis, congenital heart disease, and cardiac transplantation recipients who develop cardiac valvulopathy, history of rheumatic fever or rheumatic heart disease diagnosed by echocardiogram, or history (within 10 years prior to enrollment) of IV drug abuse

13. Active Charcot deformity of the study foot (i.e. foot is erythematous, warm, edematous, and is actively remodeling)

14. Patients with other reasons for wound healing disturbances: e.g. bleeding disorders, vitamin K deficiency, hypocalcemia, major immune deficiencies

15. Active malignant disease of any kind except for basal cell carcinoma (of the skin) not co-located with the target ulcer. A patient, who has had a malignant disease in the past, was treated and is currently disease-free and not on active treatment with an immune-suppressive therapy at least for 3 months, may be considered for study entry

16. Pregnant or lactating woman

17. Haemoglobin of less than 8.5 g/dL

18. Transaminase levels greater than 3 times ULN

19. Patients receiving haemodialysis or chronic ambulatory peritoneal dialysis (CAPD) therapy

20. Positive for hepatitis B or C virus (HBV, HCV), or human immunodeficiency virus (HIV); serology test results not older than 3 months are accepted

21. Planned surgery during the study period

22. Known abuse of alcohol, drugs, or medical products. Tobacco use will be allowed

23. Previous participation in this clinical study

24. Any diagnosed unstable condition that could interfere with compliance, such as psychiatric disorder

25. Myocardial infarction diagnosed within last 3 months prior to start of screening/run-in period

26. Confirmed or suspected COVID-19 infection.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aurealis Oy

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Medizinische Hochschule Hannover (MHH) CRC Core Facility

Hanover, , Germany

Mikomed

Lodz, , Poland

Countries

Germany; Poland

References

Schindler C, Mikosinski J, Mikosinski P, Karkkainen HR, Sanio M, Kurkipuro J, Mierau I, Smith W, Vartiainen A, Decory L, Weber D, Wirth T, Yrjanheikki J, Schellong S, Samaranayake H. Multi-target gene therapy AUP1602-C to improve healing and quality of life for diabetic foot ulcer patients: a phase I, open-label, dose-finding study. Ther Adv Endocrinol Metab. 2024 Nov 4;15:20420188241294134. doi: 10.1177/20420188241294134. eCollection 2024.

Reference Type: DERIVED

PMID: 39838970 (View on PubMed)

Other Identifiers

2018-003415-22

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

AP-W-CLI-2018-8

Identifier Type: -

Identifier Source: org_study_id